Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA) has announced upcoming encore presentations of top-line data from their pivotal Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution for treating autoimmune Pulmonary Alveolar Proteinosis (aPAP). The presentations will be featured at two major scientific conferences:

1. The 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany (April 9-12, 2025), where Dr. Francesco Bonella will present findings showing molgramostim's improvements in pulmonary gas exchange, quality of life, and exercise capacity in aPAP patients.

2. The 65th Annual Meeting of the Japanese Respiratory Society (JRS) in Tokyo, Japan (April 11-13, 2025), where Dr. Yoshikazu Inoue will present the IMPALA-2 Phase 3 trial results.

The presentations will subsequently be made available on Savara's corporate website under the Congresses & Publications section.

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65^th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April 9-12 and at the 65^th Annual Meeting of the Japanese Respiratory Society (JRS) taking place April 11-13, 2025, in Tokyo, Japan.

DGP 2025 Virtual Presentation

Poster Title: Inhaled Molgramostim Improves Pulmonary Gas Exchange, Quality of Life, and Exercise Capacity in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Session: Interstitial Lung Disease, Pulmonary Hypertension, Lung Cancer & Infections
Date/Time of Poster Discussion Session: April 9, 2025, 14:05 – 14:10 CEST
Presenter: Francesco Bonella, M.D., Center for Interstitial and Rare Lung Disease, Pneumology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany

For more information about the 65^th Congress of the DGP, please visit their website.

JRS 2025 Poster

Poster Title: Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial
Session: English Poster Discussion “Rare Disease”
Date/Time of Poster Discussion Session: April 12, 2025, 14:15 – 14:30 JST
Abstract Number: EPD65
Poster Number: 65
Presenter: Yoshikazu Inoue, M.D., Clinical Research Center, NHO Kiniki Chuo Chest Medical Center and Internal Medicine, Osaka Anti-Tuberculosis Association Osaka Fukujuji Hospital, Osaka, Japan

For more details about the JRS Annual Meeting, please visit their website.

Following the sessions, the presentations will be available on the Congresses & Publications page of the Savara corporate website.

About Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
aPAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.

About Savara
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow^® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250407996107/en/

Media and Investor Relations Contact

Savara Inc.

Temre Johnson, Executive Director, Corporate Affairs

ir@savarapharma.com

Source: Savara Inc.

FAQ

What are the key findings of Savara's (SVRA) Phase 3 IMPALA-2 trial for molgramostim?

The trial showed that inhaled molgramostim improved pulmonary gas exchange, quality of life, and exercise capacity in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Where will Savara (SVRA) present the IMPALA-2 trial results in 2025?

The results will be presented at the 65th Congress of the German Society of Pneumology in Leipzig (April 9-12) and the 65th Annual Meeting of the Japanese Respiratory Society in Tokyo (April 11-13).

Who are the key presenters for SVRA's IMPALA-2 trial data in 2025?

Dr. Francesco Bonella will present at DGP in Germany, and Dr. Yoshikazu Inoue will present at JRS in Japan.

What condition does Savara's (SVRA) molgramostim treatment target?

Molgramostim targets autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare respiratory disease.